Cargando…

An engineered HIV-1 Gag-based VLP displaying high antigen density induces strong antibody-dependent functional immune responses

Antigen display on the surface of Virus-Like Particles (VLPs) improves immunogenicity compared to soluble proteins. We hypothesised that immune responses can be further improved by increasing the antigen density on the surface of VLPs. In this work, we report an HIV-1 Gag-based VLP platform engineer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tarrés-Freixas, Ferran, Aguilar-Gurrieri, Carmen, Rodríguez de la Concepción, María Luisa, Urrea, Victor, Trinité, Benjamin, Ortiz, Raquel, Pradenas, Edwards, Blanco, Pau, Marfil, Sílvia, Molinos-Albert, Luis Manuel, Barajas, Ana, Pons-Grífols, Anna, Ávila-Nieto, Carlos, Varela, Ismael, Cervera, Laura, Gutiérrez-Granados, Sònia, Segura, María Mercedes, Gòdia, Francesc, Clotet, Bonaventura, Carrillo, Jorge, Blanco, Julià
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10077320/ https://www.ncbi.nlm.nih.gov/pubmed/37024469 http://dx.doi.org/10.1038/s41541-023-00648-4

Ejemplares similares

Exploring FeLV-Gag-Based VLPs as a New Vaccine Platform—Analysis of Production and Immunogenicity
por: Ortiz, Raquel, et al.
Publicado: (2023)

Impact of hybrid immunity booster vaccination and Omicron breakthrough infection on SARS-CoV-2 VOCs cross-neutralization
por: Pradenas, Edwards, et al.
Publicado: (2023)

Virological and Clinical Determinants of the Magnitude of Humoral Responses to SARS-CoV-2 in Mild-Symptomatic Individuals
por: Pradenas, Edwards, et al.
Publicado: (2022)

SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity
por: Trinité, Benjamin, et al.
Publicado: (2021)

Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection
por: Pradenas, Edwards, et al.
Publicado: (2022)

Impact of chemotherapy and/or immunotherapy on neutralizing antibody response to SARS‐CoV‐2 mRNA‐1237 vaccine in patients with solid tumors
por: Felip, Eudald, et al.
Publicado: (2022)

Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes
por: Pradenas, Edwards, et al.
Publicado: (2021)

Previous SARS-CoV-2 Infection Increases B.1.1.7 Cross-Neutralization by Vaccinated Individuals
por: Trinité, Benjamin, et al.
Publicado: (2021)

Characterization and quantitation of fluorescent Gag virus-like particles
por: Gutiérrez-Granados, Sonia, et al.
Publicado: (2013)

Heterogeneous Infectivity and Pathogenesis of SARS-CoV-2 Variants Beta, Delta and Omicron in Transgenic K18-hACE2 and Wildtype Mice
por: Tarrés-Freixas, Ferran, et al.
Publicado: (2022)

Alanine-based spacers promote an efficient antigen processing and presentation in neoantigen polypeptide vaccines
por: Aguilar-Gurrieri, Carmen, et al.
Publicado: (2023)

Anti-MPER antibodies with heterogeneous neutralization capacity are detectable in most untreated HIV-1 infected individuals
por: Molinos-Albert, Luis M, et al.
Publicado: (2014)

Gp120/CD4 Blocking Antibodies Are Frequently Elicited in ART-Naïve Chronically HIV-1 Infected Individuals
por: Carrillo, Jorge, et al.
Publicado: (2015)

Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Hyperimmune Immunoglobulin Demonstrates Potent Neutralization and Antibody-Dependent Cellular Cytotoxicity and Phagocytosis Through N and S Proteins
por: Díez, José María, et al.
Publicado: (2021)

Immunologic Insights on the Membrane Proximal External Region: A Major Human Immunodeficiency Virus Type-1 Vaccine Target
por: Molinos-Albert, Luis M., et al.
Publicado: (2017)

Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity
por: Carrillo, Jorge, et al.
Publicado: (2021)

First Detection of SARS-CoV-2 Delta (B.1.617.2) Variant of Concern in a Dog with Clinical Signs in Spain
por: Fernández-Bastit, Leira, et al.
Publicado: (2021)

Glucocorticoids’ treatment impairs the medium-term immunogenic response to SARS-CoV-2 mRNA vaccines in Systemic Lupus Erythematosus patients
por: Garcia-Cirera, Silvia, et al.
Publicado: (2022)

Gag Virus-like Particles Functionalized with SARS-CoV-2 Variants: Generation, Characterization and Recognition by COVID-19 Convalescent Patients’ Sera
por: Boix-Besora, Arnau, et al.
Publicado: (2023)

Efficacy of SARS-CoV-2 vaccination in patients with monoclonal gammopathies: A cross sectional study
por: Abella, Eugenia, et al.
Publicado: (2022)

Differential N‐ and O‐glycosylation signatures of HIV‐1 Gag virus‐like particles and coproduced extracellular vesicles
por: Lavado‐García, Jesús, et al.
Publicado: (2022)

A Four-Step Purification Process for Gag VLPs: From Culture Supernatant to High-Purity Lyophilized Particles
por: González-Domínguez, Irene, et al.
Publicado: (2021)

Optimization, Production, Purification and Characterization of HIV-1 GAG-Based Virus-like Particles Functionalized with SARS-CoV-2
por: Boix-Besora, Arnau, et al.
Publicado: (2022)

Use of the piggyBac transposon to create HIV-1 gag transgenic insect cell lines for continuous VLP production
por: Lynch, Alisson G, et al.
Publicado: (2010)

Induction of HIV-1 Gag-specific memory T cells in Chacma baboons by MVA prime and VLP boost vaccine regimen
por: Singh, V, et al.
Publicado: (2012)

Chimeric VLPs Based on HIV-1 Gag and a Fusion Rabies Glycoprotein Induce Specific Antibodies against Rabies and Foot-and-Mouth Disease Virus
por: Fontana, Diego, et al.
Publicado: (2021)

PEI-Mediated Transient Transfection of High Five Cells at Bioreactor Scale for HIV-1 VLP Production
por: Puente-Massaguer, Eduard, et al.
Publicado: (2020)

HIV-1 trans-Infection Mediated by DCs: The Tip of the Iceberg of Cell-to-Cell Viral Transmission
por: Perez-Zsolt, Daniel, et al.
Publicado: (2021)

Antibodies and Antibody Derivatives: New Partners in HIV Eradication Strategies
por: Carrillo, Jorge, et al.
Publicado: (2018)

Reduced humoral response 3 months following BNT162b2 vaccination in SARS-CoV-2 uninfected residents of long-term care facilities
por: Trigueros, Macedonia, et al.
Publicado: (2022)

Preserved immune functionality and high CMV-specific T-cell responses in HIV-infected individuals with poor CD4(+) T-cell immune recovery
por: Gómez-Mora, Elisabet, et al.
Publicado: (2017)

Low levels of anti-MPER antibodies are detectable in viremic HIV infected
por: Carrillo, J, et al.
Publicado: (2012)

SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells
por: Perez-Zsolt, Daniel, et al.
Publicado: (2021)

Author Correction to: SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells
por: Perez-Zsolt, Daniel, et al.
Publicado: (2022)

Comparisons of Antibody Populations in Different Pre-Fusion F VLP-Immunized Cotton Rat Dams and Their Offspring
por: Cullen, Lori M., et al.
Publicado: (2020)

Control of HIV-1 Pathogenesis in Viremic Nonprogressors Is Independent of Gag-Specific Cytotoxic T Lymphocyte Responses
por: Salgado, Maria, et al.
Publicado: (2018)

A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV
por: Negredo, Eugènia, et al.
Publicado: (2020)

The HR2 polymorphism N140I in the HIV-1 gp41 combined with the HR1 V38A mutation is associated with a less cytopathic phenotype
por: Cunyat, Francesc, et al.
Publicado: (2012)

Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions
por: Llano, Anuska, et al.
Publicado: (2013)

HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy
por: Blanch-Lombarte, Oscar, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g0khmpi1gnh3uor7i2lg6i4g31